Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| 7.4 | |
| 7.73 | |
| - | |
| 7.9 | |
| 7.27 | |
| 4.585-20.58 | |
| 645 M | |
| 83 966 K | |
| 16 049 K | |
| -0.59 | |
| 1.833 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The ARK Innovation ETF (NYSEARCA:ARKK) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One o...
Biotech stocks, namely those involved with gene editing, have been explosive. Just look at CRISPR Therapeutics (NASADQ:CRSP), for example. Since late October, CRSP rocketed from about $40 a share to...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
